logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Jubilant Pharmova Ltd

Jubilant Pharmova

Mid Cap•5,399 Employees•IPO 1994
Current Price
₹834.30
-16.05 (-1.89%)Updated
NSE :JUBLPHARMA
BSE :530019
Sector :Pharmaceuticals
Today's Range
₹824.60
₹834.30
union icon
₹847.50
52 Week Range
52W Low₹802.00
52W High₹1248.00
₹834.30
union icon
Downside4.03%
Upside49.59%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹14,306.63 Cr
Market Cap
Total market value of company
P/E Ratio
33.06
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
2.59
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹27.23
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
4.26%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
9.54%
ROCE
Return on Capital Employed. >15% is good
Net Margin
5.46%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-1.33%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
3.90%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
9.76%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-3.72%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.44
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹394.81
Book Value
Net asset value per share
Dividend Yield
0.56%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
47.70%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

3 points
  • •Jubilant Pharmova boasts a robust market capitalization of ₹18082 crore, indicating significant investor confidence and substantial company value. Its strong promoter holding of 47.7% suggests a high degree of management commitment and long-term vision for the company's growth and success.
  • •The company shows a healthy operating profit margin (OPM) of 16.40%, demonstrating efficient cost management and strong pricing power within its pharmaceutical sector. This profitability is further supported by a Return on Equity (ROE) of 9.55%, suggesting effective utilization of shareholder investments.

Weaknesses

5 points
  • •Jubilant Pharmova's Price-to-Earnings (PE) ratio of 37.20 is relatively high, potentially indicating the stock might be overvalued compared to its earnings. Investors should carefully assess the company's future growth prospects to justify this valuation.
  • •The company's recent quarterly profit growth has been volatile, showing a negative variation of -3.72%. This inconsistency in profitability raises concerns about the sustainability of its earnings and requires further investigation into the underlying causes.

Opportunities

2 points
  • •The pharmaceutical sector, where Jubilant Pharmova operates, is experiencing robust growth driven by increasing healthcare demand, R&D advancements, and expanding global markets. This provides a favorable environment for sustained revenue expansion.
  • •Expansion into new therapeutic areas or emerging markets presents a significant growth opportunity for Jubilant Pharmova. Diversifying its product portfolio could reduce dependency on existing segments and unlock new revenue streams.

Threats

3 points
  • •Intense competition from larger, more established players like Sun Pharma and Divi's Lab, who boast significantly higher market caps and ROCE, poses a substantial threat to Jubilant Pharmova's market share and profitability.
  • •Strict and evolving regulatory landscapes in the pharmaceutical industry, including drug pricing controls and approval processes, could impact Jubilant Pharmova's operational flexibility and profitability margins.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Jubilant Enpro Private Limited
13 Jun 202516 Jun 2025-
21.16 L
₹1,060SELL
SPB Trustee Company Private Limited and SS Trustee Company Private Limited
13 Jun 202516 Jun 20253.20 Cr
7.00 L
₹1,060SELL
Nikita Resources Private Limited
13 Jun 202516 Jun 202515.42 L
19.62 L
₹1,060.37SELL

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹892.13+₹57.83+6.93%
R3₹869.23+₹34.93+4.19%
R2₹858.37+₹24.07+2.88%
R1₹846.33+₹12.03+1.44%
PIVOT₹835.471.170.14%
CURRENT₹834.30--
S1₹777.63-₹56.67-6.79%
S2₹800.53-₹33.77-4.05%
S3₹812.57-₹21.73-2.60%
S4₹823.43-₹10.87-1.30%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.25L
(04 Mar 2026)
-20.6% vs avg
Delivery %
59.6%
(04 Mar 2026)
+9.2% vs avg
Avg Volume (20D)
1.58L
(04 Feb - 04 Mar)
20-day average
Avg Delivery %
50.4%
(04 Feb - 04 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Pfizer Ltd
3.28 %

Peer Comparison

Company Name
ACUTAAS
Acutaas Chemicals Ltd
AETHER
Aether Industries Ltd
APLLTD
Alembic Pharmaceuticals Ltd
CAPLIPOINT
Caplin Point Laboratories Ltd
COHANCE
Cohance Lifesciences Ltd
CONCORDBIO
Concord Biotech Ltd
ERIS
ERIS Lifesciences Ltd
GRANULES
Granules India Ltd
NATCOPHARM
Natco Pharma Ltd
NEULANDLAB
Neuland Laboratories Ltd
PFIZER
Pfizer Ltd
PPLPHARMA
Piramal Pharma Ltd
RUBICON
SANOFICONR
Sanofi Consumer Healthcare India Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
WOCKPHARMA
Wockhardt Ltd

About

JUBLPHARMA

Jubilant Pharmova Ltd

Jubilant Pharmova Limited is a globally integrated pharmaceutical company with a presence in India, the Americas, Europe, and other international markets. The company's operations are structured across six distinct segments, each contributing to its diverse portfolio of products and services within the pharmaceutical industry.

The Radiopharma segment focuses on the development and supply of radiopharmaceuticals. These specialized products play a crucial role in the diagnosis and treatment of various conditions, including cancer, pulmonary embolism, and coronary artery disease. This segment caters to the needs of healthcare providers requiring advanced diagnostic and therapeutic tools.

The Allergy Immunotherapy segment specializes in providing diagnostic tools for allergy testing, along with the production and distribution of venom and allergy immunotherapy products. This segment addresses the growing need for effective allergy management and treatment, targeting allergists and healthcare facilities.

Jubilant Pharmova's Contract Development and Manufacturing Organisation (CDMO) – Sterile Injectables segment offers contract manufacturing services for a wide range of sterile injectable products. This includes liquids, ointments, creams, and ampoules. The company acts as a manufacturing partner for other pharmaceutical companies, providing expertise and capacity in sterile injectables production.

The Generics segment focuses on the development, manufacturing, distribution, and marketing of generic pharmaceutical formulations across various therapeutic areas. These areas include cardiovascular health, central nervous system disorders, gastrointestinal issues, antibiotics, and other multispecialty treatments. This segment competes in the broader market for affordable and accessible medications.

Another CDMO segment, focusing on Contract Research, Development, and Manufacturing Organisation, provides comprehensive drug discovery and development services, including the production of Active Pharmaceutical Ingredients (APIs). This segment plays a crucial role in supporting the pharmaceutical industry's research and development efforts.

Finally, the Proprietary Novel Drugs segment concentrates on developing and delivering patient-focused biopharmaceutical solutions addressing unmet medical needs primarily in oncology and autoimmune diseases. This segment reflects the company's commitment to innovation and the development of novel treatments for serious illnesses.

In summary, Jubilant Pharmova operates across the pharmaceutical value chain, from research and development to manufacturing and distribution, serving a diverse range of clients including pharmaceutical companies, biotech firms, group purchasing organizations, allergists, and hospitals. The company's diversified business model positions it for growth and adaptability within the dynamic global pharmaceutical landscape.

COMPANY FACTS - JUBLPHARMA

Registered Address

1A, Sector 16A

Noida

UTTAR PRADESH

IN

Tel: 911204361000

Website:https://www.jubl.com/

Investor Relations:http://www.jubilantpharmova.com/investors/financials/annual-reports
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 5,399

IPO Date: 09/11/1994

MANAGEMENT - JUBLPHARMA

Mr. Hari Bhartia

Non-Executive Co-Chairman of the Board

Mr. Shyam Bhartia

Non-Executive Chairman of the Board

Mr. Arvind Chokhany

Group Chief Financial Officer, Whole-Time Director

Mr. Naresh Kapoor

Compliance Officer, Company Secretary

Mr. Arjun Bhartia

Joint Managing Director, Executive Director

Shri. Priyavrat Bhartia

Managing Director, Executive Director

Dr. Arul Ramakrishan

Whole-Time Director

Mr. Shirish Belapure

Non-Executive Independent Director

Dr. Harsh Mahajan

Non-Executive Independent Director

Mr. Vivek Mehra

Non-Executive Independent Director

Ms. Shivpriya Nanda

Non-Executive Independent Director

Mr. Sushil Roongta

Non-Executive Independent Director

Investor Questions Answered

Jubilant Pharmova Ltd (JUBLPHARMA) Stock FAQs

Get answers to the most common questions about Jubilant Pharmova Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Jubilant Pharmova Ltd (JUBLPHARMA) is ₹834.3. Today, the stock has declined by ₹16.05 (1.89%), trading in a range of ₹824.6 to ₹847.5. The stock opened at ₹845 with a trading volume of 1,25,180 shares.
Jubilant Pharmova Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹14,306.63 crores, P/E ratio of 33.06, ROE of 4.26%, and ROCE of 9.54%. The dividend yield stands at 0.56%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Jubilant Pharmova Ltd (JUBLPHARMA) is ₹1,248, while the 52-week low is ₹802. Currently trading at ₹834.3, the stock is 7.2% away from its 52-week low and 33.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Jubilant Pharmova Ltd stock at ₹834.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 33.06 and P/B ratio of N/A. Today's performance shows a loss of 1.89%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Jubilant Pharmova Ltd offers a dividend yield of 0.56%, which means for every ₹100 invested at the current price of ₹834.3, you can expect to receive approximately ₹0.56 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Jubilant Pharmova Ltd's key financial metrics include: P/E Ratio: 33.06, P/B Ratio: N/A, ROE: 4.26%, ROCE: 9.54%, Dividend Yield: 0.56%, EPS: ₹27.23, Book Value: ₹394.81, Debt-to-Equity: 0.44, and Current Ratio: N/A. The company's market cap stands at ₹14,306.63 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Jubilant Pharmova Ltd stock opened at ₹845 and is currently trading at ₹834.3, showing a decline of ₹16.05 (1.89%). The intraday high is ₹847.5 and low is ₹824.6. The trading volume stands at 1,25,180 shares, indicating moderate market participation today.
Jubilant Pharmova Ltd has a Price-to-Earnings (P/E) ratio of 33.06, which means investors are willing to pay ₹33.06 for every ₹1 of earnings. With an EPS of ₹27.23, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Jubilant Pharmova Ltd has a market capitalization of ₹14,306.63 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹834.3) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Jubilant Pharmova Ltd has a book value of ₹394.81 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹834.3, which is 111.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Jubilant Pharmova Ltd has a Return on Equity (ROE) of 4.26% and Return on Capital Employed (ROCE) of 9.54%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Jubilant Pharmova Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Jubilant Pharmova Ltd has a debt-to-equity ratio of 0.44, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Jubilant Pharmova Ltd has an Earnings Per Share (EPS) of ₹27.23, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹834.3 and P/E ratio of 33.06, investors are paying 33.06 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Jubilant Pharmova Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Jubilant Pharmova Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Jubilant Pharmova Ltd stock, consider: 1) Fundamental Analysis - Review P/E (33.06), ROE (4.26%), debt-to-equity (0.44), and growth rates. 2) Technical Analysis - Check 52-week range (₹802.00 - ₹1248.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹834.30) with book value (₹394.81) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Jubilant Pharmova Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹834.3 is 83330x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Jubilant Pharmova Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹802.00 - ₹1248.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.44 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,25,180 shares. 5) Valuation Risk - P/E of 33.06 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Jubilant Pharmova Ltd operates in the industry with key metrics: P/E ratio of 33.06, ROE of 4.26%, market cap of ₹14,306.63 crores, and dividend yield of 0.56%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.44), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Jubilant Pharmova Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹834.3, with a 52-week range of ₹802.00 to ₹1248.00. Based on fundamentals like P/E (33.06), ROE (4.26%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Jubilant Pharmova Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹834.30. 2) Fundamental Deterioration - Declining ROE (currently 4.26%), increasing debt (D/E: 0.44), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Jubilant Pharmova Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.56%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.